Relevant bibliographies by topics / Hypotensive effect of apelin

Contents

  1. Journal articles

Academic literature on the topic 'Hypotensive effect of apelin'

Author: Grafiati
Published: 19 July 2023

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the lists of relevant articles, books, theses, conference reports, and other scholarly sources on the topic 'Hypotensive effect of apelin.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Journal articles on the topic "Hypotensive effect of apelin"

1

Lee, Dennis K., Victor R. Saldivia, Tuan Nguyen, Regina Cheng, Susan R. George, and Brian F. O’Dowd. "Modification of the Terminal Residue of Apelin-13 Antagonizes Its Hypotensive Action." Endocrinology 146, no. 1 (2005): 231–36. http://dx.doi.org/10.1210/en.2004-0359.

Full text
Abstract:
The apelin peptide is the endogenous ligand for the apelin G protein-coupled receptor. The distribution of the apelin peptides and receptor are widespread in the central nervous system and periphery, with reported roles in the hypothalamic-pituitary-adrenal axis, blood pressure regulation and as one of the most potent positive inotropic substances yet identified. In this report, we show that in native tissues preproapelin exists as a dimer. Dimeric preproapelin was reduced to monomers by dithiothreitol treatment, indicating disulfide linkages. To evaluate the role of the carboxyl-terminal phenylalanine in the hypotensive action of apelin-13, analogs were generated and tested for their role on blood pressure regulation. Injections of apelin-13 and apelin-12 (15 μg/kg) into spontaneously hypertensive rats lowered systolic and diastolic blood pressure to result in decreases of approximately 60% and 15% in mean arterial blood pressure, respectively. Apelin-13(13[d-Phe]) treatment did not differ from apelin-13 in either efficacy or duration of effect, whereas apelin-13(F13A) revealed a loss of function. However, concomitant administration of apelin-13(F13A) (30 μg/kg) blocked hypotensive effects of apelin-13 (15 μg/kg), which revealed that apelin-13(F13A) behaved as an apelin-specific antagonist.
APA, Harvard, Vancouver, ISO, and other styles
2

Fernandez, Kleinberg X., Conrad Fischer, Jennie Vu, et al. "Metabolically stable apelin-analogues, incorporating cyclohexylalanine and homoarginine, as potent apelin receptor activators." RSC Medicinal Chemistry 12, no. 8 (2021): 1402–13. http://dx.doi.org/10.1039/d1md00120e.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Besserer-Offroy, Élie, Patrick Bérubé, Jérôme Côté та ін. "The hypotensive effect of activated apelin receptor is correlated with β-arrestin recruitment". Pharmacological Research 131 (травень 2018): 7–16. http://dx.doi.org/10.1016/j.phrs.2018.02.032.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Zhang, Rong, Jingyi Lu, Cheng Hu, et al. "Associations of Common Variants atAPLNand Hypertension in Chinese Subjects with and without Diabetes." Experimental Diabetes Research 2012 (2012): 1–6. http://dx.doi.org/10.1155/2012/917496.

Full text
Abstract:
Background. Apelin, the endogenous ligand for the APJ receptor, has a potent hypotensive effect via a nitric oxide-dependent mechanism in vivo. The aim of the study was to investigate the association between the common variants of apelin gene (APLN) and hypertension, which was reported recently in a Chinese Han population with and without diabetes.Methods. Three single nucleotide polymorphisms (SNPs) onAPLNwere genotyped in 3156 diabetic patients and 3736 nondiabetic individuals. For non-diabetic subjects, 1779 were enrolled in stage 1 and 1757 were recruited for validation. A meta-analysis combining the two stages was carried out to obtain the overall effect.Results. In diabetic patients, no significant associations of the three SNPs with hypertension were observed. In contrast, we found that rs2235306 was associated with hypertension in non-diabetic males after adjusting for covariates (OR=1.19,P=0.039) while rs2235307 and rs3115759 displayed no evidence of association in both genders. One haplotype, C-C-A, also showed an association with hypertension (OR=1.47,P=0.032) only in men. However, analysis in stage 2 and meta-analysis did not support these findings.Conclusions. We conclude that common variants onAPLNare not associated with the prevalence of hypertension in the Chinese.
APA, Harvard, Vancouver, ISO, and other styles
5

Trojanowicz, Bogusz, Christof Ulrich, and Matthias Girndt. "Uremic Apelin and Leucocytic Angiotensin-Converting Enzyme 2 in CKD Patients." Toxins 12, no. 12 (2020): 742. http://dx.doi.org/10.3390/toxins12120742.

Full text
Abstract:
Apelin peptides (APLN) serve as second substrates for angiotensin-converting enzyme 2 (ACE2) and, in contrast to angiotensin II (AngII), exert blood-pressure lowering and vasodilatation effects through binding to G-coupled APLN receptor (APLNR). ACE2-mediated cleavage of the APLN may reduce its vasodilatory effects, but decreased ACE2 may potentiate the hypotensive properties of APLN. The role of APLN in uremia is unclear. We investigated the correlations between serum-APLN, leucocytic APLNR, and ACE2 in 32 healthy controls (NP), 66 HD, and 24 CKD3–5 patients, and the impact of APLN peptides on monocytic behavior and ACE2 expression under uremic conditions in vitro. We observed that serum APLN and leucocytic APLNR or SLCO2B1 were significantly elevated in uremic patients and correlated with decreased ACE2 on uremic leucocytes. APLN-treated THP-1 monocytes revealed significantly increased APLNR and ACE2, and reduced TNFa, IL-6, and MCSF. Uremic toxins induced a dramatic increase of miR-421 followed by significant reduction of ACE2 transcripts, partially counteracted with APLN-13 and -36. APLN-36 triggered the most potent transmigration and reduction of endothelial adhesion. These results suggest that although APLN peptides may partly protect against the decay of monocytic ACE2 transcripts, uremic milieu is the most dominant modulator of local ACE2, and likely to contribute to the progression of atherosclerosis.
APA, Harvard, Vancouver, ISO, and other styles
6

Пальцын, А. А., and Н. Б. Свиридкина. "Apelin." Nauchno-prakticheskii zhurnal «Patogenez», no. 2 (June 28, 2021): 83–90. http://dx.doi.org/10.25557/2310-0435.2021.02.83-90.

Full text
Abstract:
Апелин - слово, появившееся в 1998 году. Так, по аббревиатуре рецептора APJ, авторы назвали, найденный ими лиганд этого рецептора. Существует в нескольких изоформах, от 13 до 77 аминокислотных остатков. Наиболее активна самая короткая форма: апелин-13. Образуется жировой и мышечной тканью - адипокин и миокин. В экспериментах на мышах обнаружено много положительных эффектов действия апелина, в том числе торможение развития старости. В нарастающем потоке клинических результатов есть сообщения о благоприятном действии апелина при нарушениях энергетического обмена, сердечно-сосудистой патологии, гипоксических состояниях, саркопении, ожирении, диабете. Apelin is a word that emerged in 1998. This is how the authors named the APJ receptor ligand they discovered, by the abbreviation of this receptor. Apelin exists in several isoforms ranging in size from 13 to 77 amino acid residues. The shortest form, apelin-13, is the most active one. Apelin is produced by adipose and muscle tissue as an adipokine and a myokine. Experiments on mice have shown multiple beneficial effects of apelin, including slowing the ageing process. In the growing stream of clinical results, there are reports of the beneficial effect of apelin in disorders of energy metabolism, cardiovascular diseases, hypoxic conditions, sarcopenia, obesity, and diabetes mellitus.
APA, Harvard, Vancouver, ISO, and other styles
7

SUZUKI, KEIKO. "Studies on estimation of hypotensive effect by hypotensive drugs." Rinsho yakuri/Japanese Journal of Clinical Pharmacology and Therapeutics 21, no. 1 (1990): 143–44. http://dx.doi.org/10.3999/jscpt.21.143.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Abdul-Ghani, A. S., R. Amin, and M. S. Suleiman. "Hypotensive Effect ofCrataegus oxyacantha." International Journal of Crude Drug Research 25, no. 4 (1987): 216–20. http://dx.doi.org/10.3109/13880208709055196.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Villar, A., M. J. Sanz, and M. Paya. "Hypotensive Effect ofPistacia lentiscusL." International Journal of Crude Drug Research 25, no. 1 (1987): 1–3. http://dx.doi.org/10.3109/13880208709060902.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

PRIETO, Juan Carlos, Mónica QUEVEDO, Hugo F. MIRANDA, and Gianni PINARDI. "Hypotensive effect of dopamine." Acta Cardiologica 60, no. 3 (2005): 253–57. http://dx.doi.org/10.2143/ac.60.3.2005004.

Full text
APA, Harvard, Vancouver, ISO, and other styles
More sources
You might also be interested in the extended bibliographies on the topic 'Hypotensive effect of apelin' for particular source types:
Journal articles
We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!

To the bibliography